PREFER – Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle

This project, lasting five years, is due to start in October 2016.

It has recently been financed under the European programme Innovative Medicines Initiative (IMI), within the ambit of research and intervention relating to the needs of patients and their involvement in the drug production cycle.

The project is the result of the collaboration of 32 European and US partners from the academic/public and industrial fields, and it aims to develop and implement methodologies suitable for recognizing and eliciting patient preferences regarding  drug intake.

In particular, Professor Pravettoni’s team will  investigate decision-making processes and the psycho-cognitive and emotional factors involved in arriving at preferences.

The research activity and the case studies conducted, will enable the drawing up of specific guidance to be adopted in the process of inclusion of patient preferences in the production cycle of a drug.